<DOC>
	<DOC>NCT00884715</DOC>
	<brief_summary>Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.</brief_summary>
	<brief_title>Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome</brief_title>
	<detailed_description>This study will evaluate a longer acting octreotide formulation. A subcutaneous implant at 2 doses will be evaluated for pharmacodynamics, efficacy and safety for a period of 9 months.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>histologically confirmed tumor documented evidence of carcinoid syndrome life expectancy of at least 6 months previous positive octreotide scan received stable doses of octreotide injections performance status of 02 on the ECOG performance scale poorly differentiated or high grade neuroendocrine tumor significant cv, hepatic, renal or other disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>